The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: bullous skin disease following therapy with immune checkpoint inhibitor
Parameters:
(1) percent of body surface area (BSA)
(2) erythema
(3) patient impact
(4) other findings
|
BSA
|
Erythema
|
Impact
|
Other
|
Grade
|
|
0 to 10%
|
none
|
none or minimal
|
may be asymptomatic
|
G1
|
|
10 to 30%
|
NA
|
affects QOL
|
requires intervention
|
G2
|
|
> 30%
|
NA
|
limits self-care ADL (disabling)
|
sloughing with associated pain
|
G3
|
|
> 30%
|
NA
|
NA
|
associated fluid and electrolyte abnormalities
|
G4
|
